The 39th Pharmacometric Approach Group in Japan (PAGJa) Annual Meeting
We are pleased to announce that the 39th PAGJa Annual Meeting will be held on 17th November 2023 at Fujiwara Hiroshi Hall, Kyoseikan, Keio University (Yokohama, Kanagawa; please see https://www.kcc.keio.ac.jp/english/access.html).
If you would like to participate, please register from this link or send an e-mail to the conference chair (pmx2023@pagja.org). The advanced registration deadline is 10th November 2023.
Registration Fee
PAGJa 2023: Free for student, and 5,000 JPY for non-student.
Reception Party: 3,000 JPY for student, and 5,000 JPY for non-student.
Program
12:30-12:35 pm Opening Remarks
12:35-1:35 pm Educational Session
Establishing Trust and Confidence in Physiologically-Based Pharmacokinetic Models Using the Credibility Assessment Framework
Christopher Gibson, Merck & Co.
1:35-2:25 pm General Oral Presentation Session (Presented in Japanese only)
Population Pharmacokinetic Analysis for Evaluating Effect of Ethnicity on Esketamine Pharmacokinetics
Minaka Shibuya, Janssen Pharmaceutical of Johnson and Johnson
Population Pharmacokinetic Analysis Considering an Absorption Process of Mycophenolic acid
Yuki Suzuki, Nihon University
Integrated Population Pharmacokinetic Model Development of Vancomycin Applied to Diverse Patient Characteristics
Moeko Suzuki, Tokyo Women’s Medical University Hospital
2:40-3:40 pm Keynote Lecture
Convergence – Reshaping the future of Healthcare Analytics
Vijay Ivaturi, University of Maryland
3:40-5:50 pm PMDA session 2023: Industry, Government and Academia Round-table Discussion on Pharmacometrics in Pediatric Drug Development (Presented in Japanese; simultaneous translation into English will be planned for English Speaker)
Utilization of Pharmacometrics and Trends of Related Guidelines for Pediatric Drug Development
Shingo Watanabe, Pharmaceuticals and Medical Devices Agency
Optimal Dose Recommendation in Pediatrics using Pharmacometrics
Keizo Fukushima, Kobe Gakuin University
Utilization of Pharmacometrics for Drug Development of Rivaroxaban for Pediatrics Patients
Yui Terao, Bayer Yakuhin
Panel Discussion
5:50-6:00 pm Closing Remarks
6:10-8:00 pm Reception Party
Please feel free to contact to the conference chair if you have any questions. We look forward to seeing you at the meeting.
The 39th PAGJa Conference Chair
Satoshi Yoshiba (Daiichi Sankyo)
Yuki Iwaki (Janssen Pharmaceutical of Johnson and Johnson)
E-mail: pmx2023@pagja.org